Clinical Trials for Liver Cancer

Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adolescents and adults with metastatic adrenocortical carcinoma with symptomatic liver metastases and extrahepatic disease, ECOG 0–1, and no prior PD-1/PD-L1/CTLA-4 therapy, evaluating ablative radiotherapy to liver lesions followed by pembrolizumab. Pembrolizumab is an anti–PD-1 monoclonal antibody intended to enhance antitumor T-cell activity, with the RT combination aiming to potentiate systemic immune responses.

ClinicalTrials.gov ID: NCT06066333

A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, locally advanced/metastatic HCC and Child-Pugh B7–B8 cirrhosis, ECOG 0–2, and no prior systemic therapy receive either atezolizumab plus bevacizumab (anti–PD-L1 + anti-VEGF) or atezolizumab alone, with emphasis on safety/tolerability in this higher-risk population. Excludes high bleeding risk (e.g., recent/active variceal bleeding), significant autoimmune disease, prior checkpoint inhibitors, and TIPS for the combo cohort.

ClinicalTrials.gov ID: NCT06096779

Regorafenib and Yttrium-90 Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable HCC (Child-Pugh A–B7), no prior systemic therapy, and suitable anatomy for Y-90 TARE receive combined Y-90 radioembolization (TheraSphere) plus regorafenib, an oral multikinase inhibitor of VEGFR1–3, TIE2, KIT, RET, and RAF. Excludes major extrahepatic disease and significant comorbidities; aims to assess disease control and safety.

ClinicalTrials.gov ID: NCT06902246

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

PRIME-LRT: PRomoting IMmunotherapy Efficacy With Low-Dose Liver RT

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls adults with biopsy-proven NSCLC (excluding EGFR/ALK/ROS1/RET-altered tumors) or melanoma with radiographic liver metastases, ECOG 0–2, eligible for standard PD-1/PD-L1 checkpoint inhibitor–based therapy (± chemotherapy and/or CTLA-4 inhibition per routine practice). All patients receive standard systemic therapy plus investigational low-dose liver radiation delivered in the week before cycles 1, 2, and 3 to potentially modulate the hepatic immune microenvironment and enhance checkpoint inhibitor efficacy.

ClinicalTrials.gov ID: NCT07225036

Phase 1, Single-site, Single-arm, Clinical Imaging, and Blood-based Biomarker Trial Utilizing 18F-FSPG PET to Guide Therapy in Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with imaging- or pathology-confirmed hepatocellular carcinoma meeting LI-RADS criteria who are candidates for Y90 radioembolization monotherapy. Patients receive standard Y90, with investigational 18F-FSPG PET/CT (a glutamate analog tracer reflecting system xC−/redox-related amino acid transport activity) plus paired ctDNA blood sampling before and after treatment to assess early prediction/detection of response or resistance versus standard imaging over 12 months.

ClinicalTrials.gov ID: NCT07116486

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with resectable, liver-confined colorectal cancer metastases (≥1 lesion ≥2 cm) scheduled for standard hepatectomy undergo percutaneous implantation of an intratumoral microdevice into a liver metastasis 3–5 days pre-op, with en bloc retrieval at surgery. The device locally releases microdoses of multiple anticancer agents (e.g., FOLFOX/FOLFIRI/FOLFIRINOX components, bevacizumab, doxorubicin, and immunotherapies including botensilimab [Fc-enhanced anti–CTLA-4], balstilimab [anti–PD-1], and AGEN2373) to assess tissue-level drug diffusion and pharmacodynamic response, focusing on procedural safety/feasibility rather than systemic treatment.

ClinicalTrials.gov ID: NCT07193862

Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion (HELIO-RT)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with hepatocellular carcinoma with radiographic macrovascular invasion (ECOG 0–2, Child-Pugh A or B7; extrahepatic metastases allowed; no prior systemic therapy) are randomized after physician selection of a first-line IO regimen to receive systemic therapy alone versus the same systemic therapy plus liver SBRT (5 fractions). Systemic options are atezolizumab (PD-L1) + bevacizumab (VEGF), single-dose tremelimumab (CTLA-4) + durvalumab (PD-L1), or nivolumab (PD-1) + ipilimumab (CTLA-4) induction followed by nivolumab maintenance, with SBRT as the investigational addition.

ClinicalTrials.gov ID: NCT07166406

Repurposing Celecoxib to Overcome Resistance to Immunotherapy in Advanced HCC (RECON Study)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic, RECIST-measurable hepatocellular carcinoma (ECOG 0–2) and preserved hepatic function (excluding Child-Pugh ≥7B), without recent checkpoint inhibitor therapy (within 6 months) or significant cardiovascular/thromboembolic/GI bleeding risk, receive celecoxib (oral selective COX-2 inhibitor aimed at blocking COX-2/PGE2–mediated immunosuppression) continuously plus durvalumab (anti–PD-L1) every 28 days and a single priming dose of tremelimumab (anti–CTLA-4) on cycle 1 day 1. Treatment continues until progression or unacceptable toxicity with correlative biomarker sampling.

ClinicalTrials.gov ID: NCT07174570

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial targets adults with stage IV NSCLC involving liver metastases, excluding those with EGFR or BRAF mutations and prior liver radiation, to evaluate the impact of adding liver stereotactic ablative radiotherapy (L-SABR) to a standard regimen of anti-PD-(L)1 based immunotherapy and optional platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT05657873